|By Marketwired .||
|August 15, 2013 04:30 PM EDT||
SAN DIEGO, CA -- (Marketwired) -- 08/15/13 -- NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, is excited to announce the expansion and relocation of the Company's UK office.
The office relocation will enable NuVasive to better execute its market share taking strategy across Northern Europe. The modern two-story, 7,500-square-foot facility adds office space, increases warehousing capabilities, and provides dedicated space for staff training and surgeon events.
Russell Powers, NuVasive Executive Vice President of International, said, "The larger facility in London will allow NuVasive to increase our capabilities in key areas that align well with our international growth plans. We are adding significant sales talent and operational support to increase the penetration of our comprehensive portfolio of procedurally-integrated spine products not just in the UK, but across all of Europe."
Alex Lukianov, NuVasive Chairman and Chief Executive Officer, said, "Over the past few years, NuVasive has strategically expanded into international markets to proliferate minimally invasive spine surgery globally. Through our unique culture of Absolute Responsiveness to surgeon and hospital customers, we intend to improve more patient outcomes in the UK and around the world."
The original UK office opened in 2008, and was the Company's first office to be located abroad. With eight international offices located in Europe, Australia, and Asia, NuVasive currently has a presence in over 25 countries.
The new NuVasive UK office address: http://www.nuvasive.com/contact-us/
+44 (0) 2082-387-850
For NuVasive press materials please visit: http://www.nuvasive.com/about-us/newsroom/
NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally-integrated solutions for the spine. The Company is the 4th largest player in the $8.2 billion global spine market.
NuVasive offers a comprehensive spine portfolio of more than 80 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS®, platform for lateral spine fusion. MAS provides safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.
Having pioneered the lateral approach to spine fusion, NuVasive continues to be at the forefront of the spine industry's shift toward less invasive solutions. The Company places a large focus on clinical research and support of the Society of Lateral Access Surgery, or SOLAS®, to expand the body of clinical evidence in support of NuVasive's minimally disruptive solutions and to drive adoption of its techniques. The Company's dedication to innovation continues to spawn game-changing technology such as the PCM® motion preserving disc for the cervical spine, XLIF® Corpectomy for tumor and trauma, and Armada®, which treats adult degenerative scoliosis in a less invasive fashion. The Company has also developed procedural solutions that completely redefine and improve upon traditional procedures like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons worldwide. NuVasive is focused on becoming a $1 Billion Start-up; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation®, and Absolute Responsiveness®.
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to those risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.